 |
|
|
| |
Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy
|
| |
| |
Reported by Jules Levin
EASL 2018 April 14 Paris France
Oral Late Breaker
Anna S. Lok,1 Ira Willner,2 K. Rajender Reddy,3 Mohamed A. Hassan,4 Federico Hinestrosa,5
Mitchell L. Shiffman,6 Mark S. Sulkowski,7 Ira M. Jacobson,8 Robert S. Brown Jr,9 Giuseppe Morelli,10 Joy Peter,10 Michael W. Fried,11 Monika Vainorius,11 Larry Michael,11 Gary P. Wang,10 Bonnie Yiran Hu,12 Jens Kort,12 David R. Nelson,10
|
| |
|
|
|
|
|
